Alpha Tau Treats First European Pancreatic Cancer Patient with Alpha DaRT in ACAPELLA Clinical Trial

Key Takeaways

• Alpha Tau’s Alpha DaRT alpha-emitter radiotherapy successfully treated the first European pancreatic cancer patient in the ACAPELLA clinical trial
• The trial targets patients with locally advanced pancreatic cancer who completed mFOLFIRINOX treatment but have no standard consolidation therapy options
• Approximately 42,000 Europeans annually could benefit from this treatment approach for inoperable locally advanced pancreatic cancer

---

Alpha Tau Medical Ltd. announced a significant milestone in pancreatic cancer treatment, successfully treating the first European patient with its Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) technology in the French multicenter ACAPELLA clinical trial.

Revolutionary Treatment for Underserved Patient Population

The ACAPELLA trial represents a breakthrough approach for patients with locally advanced pancreatic cancer (LAPC) who have completed first-line mFOLFIRINOX chemotherapy. This patient population currently faces a critical treatment gap, as no standard consolidation therapy exists despite completing the best available systemic treatment.

Alpha DaRT combines alpha-emitter radiotherapeutics with capecitabine, offering a novel treatment modality for inoperable LAPC patients. The technology delivers targeted radiation directly to tumor sites while minimizing damage to surrounding healthy tissue.

Addressing a Critical Medical Need

Pancreatic cancer remains one of the most challenging malignancies to treat, with approximately 140,000 Europeans diagnosed annually. Of these cases, roughly 30% present with locally advanced, inoperable disease, representing about 42,000 patients who could potentially benefit from Alpha DaRT therapy.

The prognosis for LAPC patients remains poor even after completing standard systemic treatments. Current treatment options are limited, making innovative approaches like Alpha DaRT particularly valuable for this underserved population.

Clinical Trial Significance

The ACAPELLA trial’s European launch marks an important expansion of Alpha DaRT’s clinical development program. The multicenter design across France will provide robust data on the therapy’s efficacy and safety profile in European patients.

This milestone follows Alpha Tau’s previous clinical successes and represents the company’s commitment to addressing unmet medical needs in oncology. The trial will evaluate whether Alpha DaRT can improve outcomes for patients who have exhausted standard treatment options.

Market Impact and Future Implications

The successful treatment of the first European patient validates Alpha Tau’s technology platform and positions the company for potential regulatory advancement in the European market. If successful, Alpha DaRT could establish a new standard of care for LAPC patients, addressing a significant gap in current treatment paradigms.

---

Frequently Asked Questions

What is Alpha DaRT and how does it work?

Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is a targeted radiotherapy that delivers alpha radiation directly to tumors while minimizing damage to healthy surrounding tissue, combined with capecitabine chemotherapy.

Who is eligible for the ACAPELLA trial?

The trial enrolls patients with locally advanced, inoperable pancreatic cancer who have completed first-line mFOLFIRINOX treatment but have no standard consolidation therapy options available.

When might Alpha DaRT become widely available in Europe?

The timeline depends on ACAPELLA trial results and regulatory approval processes. The trial is currently in progress, and regulatory submissions would follow successful completion and data analysis.